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Aims: We investigated the impact of using an integrated, strip-free system compared to the use of single-
strip systems on testing frequency and glycemic control in individuals with insulin-treated diabetes.
Methods: This multinational, comparative, cluster-randomized, observational study included 311 patients
with type 1 and insulin-treated type 2 diabetes who were performing SMBG at suboptimal frequencies.
Sites were cluster-randomized to “integrated strip-free” system (EXP group) or any “single-strip” system
(CNL group). Testing frequency and HbA1c were measured at baseline, 12 weeks and 24 weeks.
Results: At week 24, the EXP group showed an increase in SMBG frequency from baseline of 4.17 tests/
week (95% CI 2.76, 5.58) compared with an increase of 0.53 tests/week (95% CI 0.73, 1.79) among CNL
patients, resulting in a between-group difference of 3.63 tests/week (p < 0.0002). Mixed-effects models for
repeated measurements (MMRM) controlling for baseline frequency of testing, country and clinical site
conﬁrmed a higher SMBG testing frequency in the EXP group compared to the CNL group, with a between-
group difference of 2.70 tests/week (p < 0.01). Univariate analysis showed greater HbA1c reductions in the
EXP group than CNL group: 0.44% (95% CI 0.59, 0.29) vs. 0.13% (95% CI 0.27, 0.01), respectively,
p < 0.0002. MMRM analyses conﬁrmed these HbA1c reductions. A greater percentage of EXP than CNL
patients achieved HbA1c reductions of 0.5%: 45.1% vs. 29.1%, respectively, p < 0.01.
Conclusions: The use of an integrated, strip-free SMBG system improved testing adherence and was
associated with improvements in glycemic control.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
ation at the 6th International Conference on Advanced Technologies & Treatments for Diabetes, 2013.
Inc. Open access under CC BY-NC-ND license.
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nating group allocation were sent out by sequence of inclusion.Self-monitoring of blood glucose (SMBG) is considered a critical
component of effective management in individuals with type 1
diabetes and insulin-treated type 2 diabetes [1,2]. Appropriate use
of SMBG can enhance self-management and support health care
providers in determining individualized recommendations re-
garding lifestyle and medication [3], and it has been demonstrated
to improve glycemic control in individuals with insulin-treated
diabetes [4e6]. Recent studies have also shown that SMBG is
beneﬁcial in individuals with non-insulin-treated type 2 diabetes
when a structured approach to testing is adopted [3,7e11].
National and international guidelines recommend frequent
(3 daily) SMBG in individuals with type 1 and type 2 diabetes who
are treated with multiple daily insulin injection (MDI) therapy,
advising these individuals to perform SMBG prior to administering
insulin in order to calculate appropriate basal and prandial insulin
dosages (with occasionally postprandial tests), at bedtime, prior to
exercise, and when symptoms of hypoglycemia are experienced
[1,12,13]. Despite these recommendations, a large proportion of
insulin-treated diabetes patients do not perform SMBG at optimal
frequencies [14,15]. Although the cost of SMBG is often cited as a
key obstacle to optimal testing frequency, inconvenience and
interference with lifestyle may be a more signiﬁcant factor in SMBG
adherence. In a study of 62 insulin-treated diabetes patients by
Nyomba and colleagues, 47% of participants reported inconve-
nience of testing as the primary reason for not performing frequent
SMBG [16].
One recent advance in SMBG that may lessen the inconvenience
of testing and, potentially, lead to greater adherence to recom-
mended SMBG regimens is the development of integrated, strip-free
systems such as the Accu-Chek Mobile System (Roche Diagnostics
GmbH, Mannheim, Germany). The Experience in Accu-Chek Inte-
grated Strip-free Systems (ExAct) study investigated the impact of
using an integrated strip-free SMBG system compared to single-strip
systems in a cohort of patients with type 1 and insulin-treated type 2
diabetes using self-adjusted insulin regimens.
Materials and methods
This 24-week, prospective, controlled, stratiﬁed, cluster-
randomized, observational, international, multicenter study assessed
changes in SMBG frequency and glycemic control in type 1 and
insulin-treated type 2 diabetes patients, using the Accu-Chek Mobile
system (experimental [EXP] group) compared with similar patients
who were using any unspeciﬁed single-strip SMBG system (control
[CNL] group). Investigators functioned independently in managing
their patients. This study was conducted in accordance with the
Declaration of Helsinki [17] and the guidelines of the International
Organization for Standardization (ISO) 14155 were followed as appli-
cable for a post-marketing study [18]. Informed consent was obtained
from each patient prior to conducting any study-related procedures.
Randomization
Sixty study sites in Germany, the UK, Italy and the Netherlands
were recruited for the study. Study inclusion required that sites
must have qualiﬁed personnel and be equipped with the appro-
priate medical facilities to fulﬁll the study requirements. Addi-
tionally, the sites were required to be associated with and under the
guidance of an independent ethics committee (IEC) to satisfy all
regulatory authority requirements and to conduct meetings on a
regular basis. Study sites were country-stratiﬁed and cluster-
randomized (1:1) to the integrated strip-free system (Accu-Chek
Mobile System) or any single-strip system study arms but notPatients
Patients were identiﬁed based on the usual care provided at the
center they routinely attended and the investigator’s assessment of
the individual patient’s clinical need. Selected patients were invited
for screening and enrollment at baseline (week 0, Visit 0). Inclusion
criteria for study participation were: 18 years of age; 1 year
duration of diagnosed diabetes; initial HbA1c value of 7.0%,
treatment with prandial insulin (regular insulin or rapid-acting
insulin analog); self-adjustment of insulin dosages at each meal;
and 12 weeks duration of SMBG at an average frequency <3.25
tests per day, using a current blood glucose meter with a minimum
data capacity of 200 blood glucose measurements. Exclusion
criteria included: use of parenterally administered drugs including,
or being metabolized to, maltose, or oral or inhaled steroids;
diagnosed with galactosemia or D-xylose malabsorption; pregnant
or breastfeeding; current or planned chemotherapy or radio-
therapy; current addiction to alcohol or other substances of abuse;
or diagnosed with psychological conditions rendering the patient
unable to understand the nature and scope of the study.
Procedures
At the screening visit (week 0), investigators established eligibility
and identiﬁed patients who might not be able to follow the recom-
mended SMBG regimen by checking the prescribing policy of the
relevant general practitioner or diabetologist. After obtaining signed
written informed consent from each patient, investigators performed
physical assessments, documentedmedical histories anddemographic
information, obtained blood samples for HbA1c measurements and
administered questionnaires to obtain patient-reported outcomes
(PRO) data. Investigators uploaded data from each patient’s current
SMBG system memories. EXP patients were trained in the use of the
integrated strip-free blood glucose monitoring system.
At follow-up visits, which occurred at weeks 12 and 24, in-
vestigators uploaded blood glucose meter data, obtained blood sam-
ples for HbA1cmeasurement, documented any adverse events and/or
changes in patients’ medications and administered PRO measures.
Blood glucose meters
Integrated strip-free SMBG-system
EXP patients used an integrated strip-free SMBG-system (Accu-
Chek Mobile system), consisting of a device that contains a
replaceable cassette that incorporates 50 tests on a continuous tape,
so that SMBG can be performed on the device. The device was
designed to lessen test complexity and reduce the number of
handling steps, which can affect patients’ adherence to recom-
mended testing frequencies [19,20]. The system also utilizes new
lancing device technology, enabling nearly pain-free testing, which
can impact patient adherence [21].
Single-strip SMBG-systems
CNL patients used any standard, currently marketed single-strip
SMBG-system from any manufacturer. It was required that the
device was capable of data capturewith a minimum capacity of 200
blood glucose measurements over a period of 4 weeks and allow
electronic upload of these data.
Provision of blood glucose meters/testing supplies
Patients in both study groups were responsible for obtaining
reimbursement for their blood glucose testing supplies from their
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participants or physicians to feel any gratitude toward the sponsor.
Because access to testing supplies varies by country, sites were
stratiﬁed within each country prior to randomization to achieve
equal access to testing supplies in both groups.
Measurements
The primary study endpoint was the change from baseline in the
mean test frequency at week 24. SMBG frequency at baseline and
follow-up visits was assessed using patients’ respective SMBG
systemmemories. Secondary endpoints assessed changes in HbA1c
(e.g., between-group differences at week 24, proportion of patients
who achieved 0.5% HbA1c reduction [high achievers] from base-
line). HbA1c was assessed at baseline and weeks 12 and 24. Vali-
dated instruments were used to assess PRO measures, including
the: SMBG survey to assess patients’ attitudes regarding blood
glucose monitoring [22]; the EQ-5D health status measure [23];
Diabetes Treatment Satisfaction Questionnaire (DTSQ) to assess
patients’ satisfaction with their treatment regimens [24,25]; and
regimen-related distress subscale from the Diabetes Distress Scale
(DDS) to assess patients’ emotional distress related to their treat-
ment regimen [26]. The investigator-developed Treatment Adher-
ence and Barriers (TAB) measure was used to assess patients’
reasons for adherence and nonadherence. All of the PRO measures
were assessed using self-administered questionnaires.
Statistical analysis
The analysis population was deﬁned as all eligible patients who
provided signed informed consent, participated in the baseline visit
and for whom at least one post-baseline observation on the primary
endpoint was available. Sample size estimation was based on the
results of a previous user survey [5]; it was assumed that the change
in test frequency frombaseline inpatients using the integrated strip-
free SMBG system and patients using single-strip SMBG systems
would differ by 3 tests per week relative to awithin-group standard
deviation of 11 tests per week. The sample size of 478 enrolled pa-
tients combined with an observed average number of 6.4 patients
per center and an assumed intra-cluster correlation of <0.01 was
considered sufﬁcient to provide at least 80%power for this study. The
primary analysis addressed the difference in changes in test fre-
quency between the two device groups, which was assessed by
means of a two-sided t-test at a signiﬁcance level of 5%. The last
observation was carried forward if 1 post-baseline value was
available to impute missing values. Mixed-effects models for
repeated measurements (MMRM) were also used to analyze the
change in average test frequency and inHbA1c frombaseline to both
follow-up visits as dependent variables [27,28]. These model-based
analyses support the evidence of the primary analyses and were
performed to address the followingobjectives to evaluate and adjust
for effects of co-factors (e.g., differences in dependent variables
among countries), adjust for differences in covariates such as the
baseline test frequency, allow formissing data under themissing-at-
random assumption [29] and account for a possible intra-cluster
correlation [27]. The analysis of HbA1c also included test fre-
quency at each visit as a time-dependent covariate. Sites with <4
patients per country and device group were pooled for analyses to
account for center effect.Within-patient variationwasmodeled as a
random effect, with unstructured covariance matrix and center as
random factor; the latter to account for a possible cluster effect [27].
High achiever rates were analyzed based on the number and
percentage of patients who achieved >0.5% HbA1c reduction from
baseline at week 24 by device group, using Fisher’s exact test.
Selected demographic and baseline variables across device groupwere compared using Fisher’s exact test for categorical variables
and the Wilcoxon rank sum test for continuous variables.
Results
Subject disposition and demographics
The study was conducted from October 2010 to July 2012 at
centers in Germany, the UK, Italy, and the Netherlands. Sixty study
centers were stratiﬁed by country and then randomized to account
for country differences in blood glucose test strip reimbursement. A
total of 55 centers (29 EXP, 26 CNL) enrolled patients and completed
the study; ﬁve centers withdrew from the study immediately
following site randomization. A total of 478 patients from 55 cen-
ters (Germany: 28 centers, n ¼ 222 [46.44%]; Italy: 10 centers,
n ¼ 119 [24.89%]; United Kingdom: 9 centers, n ¼ 75 [15.69%]; the
Netherlands: 8 centers, n ¼ 62 [12.97%]) were screened for eligi-
bility for study participation. Of 478 patients screened, 405 met
study inclusion criteria, 22 were excluded because they failed an
inclusion criteria checklist, 29 were excluded because they used an
impermissible meter at baseline, and 22 had SMBG testing fre-
quencies at baseline that exceeded study inclusion criteria. Of those
eligible, 350 patients began the study, and 311 patients had post-
baseline observations on the study primary endpoint: 144
(46.30%) in the EXP group and 167 (53.70%) in the CNL group). This
group comprised the efﬁcacy analysis sample; data analysis was
based on this population (Figure 1).
Among the population analyzed (n ¼ 311), most patients were
male (n ¼ 191; 61.41%), Caucasian (n ¼ 298; 95.82%) and aged 65
years (n ¼ 214; 68.8%). The proportion of patients with type 1 and
insulin-treated type 2 diabetes was 28.9% and 71.06%, respectively.
At baseline, some patient characteristics differed by device group
(Table 1). Most notably, EXP patients had signiﬁcantly lower mean
weekly SMBG testing frequency (11.03 vs. 12.73, p < 0.05) and
marginally higher HbA1c (8.60% vs. 8.37%, p < 0.09). These dis-
crepancies were corrected for during statistical analysis of the re-
sults, as described in the Methods section.
Changes in SMBG frequency
At week 24, EXP patients showed an average increase in SMBG
frequency of 4.17 (95% CI 2.76, 5.58) tests per week (D 0.60 tests per
day) while CNL patients showed an increase of 0.53 (95% CI 0.73,
1.79) tests per week (D 0.08 tests per day), resulting in a between-
group difference in the average weekly SMBG testing frequency of
3.63 tests/week (p< 0.0002) (Figure 2A). MMRManalyses (adjusted
data) also showed a greater increase in testing frequency from
baseline at week 24 in EXP patients (3.46 [95% CI 1.96, 4.97]) than
CNL patients (0.76 [95% CI 0.65, 2.18]), resulting in a between
group difference of 2.70 tests/week (p < 0.01). The differences in
change in test frequency were also evident at week 12 in both
univariate and MMRM analyses.
Changes in HbA1c values
At week 24, univariate analysis showed a greater decrease in
HbA1c from baseline in EXP patients than CNL patients: 0.44%
(95% CI 0.59, 0.29) vs. 0.13% (0.27, 0.01), p < 0.0002
(Figure 2B). The decreases in mean HbA1c values were greater at
week 12 for EXP patients compared with CNL patients:0.45% (95%
CI 0.59, 0.31) vs. 0.20% (95% CI 0.33, 0.07), respectively,
p < 0.02. Although the mean change in HbA1c from week 12 to
week 24 was maintained in EXP patients, CNL patients showed
slight increases in HbA1c levels between week 12 and week 24.
Similar ﬁndings were seen MMRM analysis.
Figure 1. Subject disposition.
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reductions of 0.5% at week 24: 45.14% vs. 29.09%, respectively,
p < 0.01). Reductions in mean (SD) HbA1c at week 24 among high
achievers were similar between EXP and CNL patients: 1.03
(0.69)% vs. 0.91 (0.65)%, p ¼ NS.
Changes in psychosocial measures
Analyses of aggregated PRO variables revealed no changes over
time or device group differences on any of the patient-reported
outcomes assessed in this study, which included measures of dia-
betes treatment satisfaction, diabetes-related distress or treatment.
However, sub-score analyses showed a non-signiﬁcant tendency for
slightly more positive perceived change in the frequency of hy-
perglycemia and hypoglycemia for patients in the EXP group than
in the CNL group. Additional analyses of these measures and others
will be presented in a subsequent report.Safety
The number of patients with diabetes-related events was
extremely low and similar for both device groups. One patient ran-
domized to the single-strip device group reported a diabetes-related
event that led to hospitalization. No patients died during the study
andnopatients discontinued the studydue todiabetes-related events.Discussion
This study compared the impact of a strip-free SMBG systemwith
a single-strip system on patient adherence to SMBG measurement
frequency and glycemic control. At the start of the study, patients in
both groups were performing SMBG at less than the recommended
frequency of 3 tests per day [1,12,13], which is generally required
for accurate calculation and effective adjustment of insulin dosages.
Table 1
Baseline characteristics of eligible patients
Characteristic Integrated
strip-free system
N ¼ 144
Single-strip system
N ¼ 167
p-Valuea
Age, mean years (SD) 55.04 (16.28) 58.75 (14.35) 0.035
BMI, mean kg/m2 (SD) 30.77 (6.35) 31.52 (6.51) 0.308
Test frequency per week,
mean (SD)
11.03 (6.70) 12.73 (6.99) 0.030
HbA1c, mean % (SD) 8.60 (1.17) 8.37 (1.16) 0.089
Diabetes duration, mean
years (SD)
15.58 (9.02) 16.82 (10.04) 0.263
a p-Value results from two-sided Wilcoxon rank sum test. BMI ¼ body mass in-
dex; HbA1c ¼ glycosylated hemoglobin; SD ¼ standard deviation.
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in a signiﬁcantly greater increases in mean SMBG testing frequency
compared with single-strip systems. At week 24, the mean SMBG
frequency in the strip-free system group remained signiﬁcantly
greater than baseline, while testing frequency in the single-strip
system decreased to baseline levels. Although we failed to recruit
and retain all patientswhowere approached for this study (N¼ 478),
the observed study power for the tests of treatment differences were
not adversely affected because the observed change in SMBG fre-
quency was signiﬁcantly greater (with lower standard deviation)
than anticipated.
There was a signiﬁcant association between change in HbA1c
from baseline and use of the strip-free system. As reported, the
increased SMBG frequency in the EXP group was accompanied by
signiﬁcant reductions in HbA1c values from baseline after 12
weeks, whichweremaintained throughweek 24. The improvementFigure 2. Change over time in (A) mean weekly SMBG frequency and (B) mean HbA1c
values.in glycemic control in the strip-free system group compared with
the single-strip system group also remained signiﬁcant after
multivariate analysis that included HbA1c level at baseline. More-
over, a greater proportion of patients in the EXP group achieved a
clinically relevant decrease of 0.5% in HbA1c from baseline to
week 24 compared with the CNL group.
The glycemic improvements seen in our study may be due to
more accurate and/or frequent bolus insulin dosage calculations.
Because manual calculation of bolus insulin dosages is complex and
time consuming, patients often do not perform these calculations
and, instead, rely on empirical estimates, which can lead to poor
glycemic control (hypoglycemia and hyperglycemia) [30]. Although
patients were provided no additional tools to aid in their bolus cal-
culations, it is possible that changes in their behavior regarding
SMBG frequency may have inﬂuenced their willingness to appro-
priately andmore frequently calculate their prandial insulin dosages.
A key limitation of the studywas a probable selection bias among
clinicians. As described earlier, investigating clinicians selected pa-
tients basedon their assessmentof eachpatient’s clinical need. If EXP
clinicians did, indeed, select less adherent and/or less well-
controlled patients, this would likely explain the imbalances seen
in baseline HbA1c levels and SMBG frequency. However, it would
also suggest that EXP clinicians recognized the potential value and
utility of the strip-free system relevant to these patients and that the
strip-free system achieved signiﬁcant gains in testing frequency and
HbA1c reduction with potentially more adherence-challenged pa-
tients. Although additional multivariate analyses methodologies
were performed to control for these baseline differences, we
recognize thepotential of these imbalances to inﬂuenceourﬁndings.
A more traditional randomization scheme would have limited se-
lection bias by minimizing clinician discretion at study initiation;
however, we chose a cluster-randomized study design to avoid any
potential “cross-contamination” of study participants, both patients
and clinicians, which can occur throughout the course of an un-
blinded study when “within-clinic” randomization is utilized [2].
Another possible limitation of the study was the potential in-
ﬂuence of the “novelty effect” among EXP patients. We recognize
that receiving a new blood glucose meter would likely prompt
increased SMBG frequency among patients during the ﬁrst few
weeks of the study, and that this increased frequency would then
subside over time. This was not observed in our study; the
increased SMBG frequency and associated improvements in HbA1c
that occurred between weeks 0 and 12 within the EXP group were
sustained for the duration of the study, suggesting that the
increased SMBG frequency may have provided a greater amount of
meaningful information that facilitated patients’ ability to make
more appropriate therapeutic decisions. Moreover, one might have
expected CNL patients to maintain their current monitoring fre-
quency, and even increase their frequency due to the study effect
[31]. Monitoring frequency in CNL patients showed a modest in-
crease during the ﬁrst 12 weeks of the study (signiﬁcantly less than
that achieved by EXP patients at week 12) and then declined to
baseline levels at the end of the study. Although modest HbA1c
improvements were seen in the CNL group at weeks 12, albeit,
signiﬁcantly less than that achieved by EXP patients, CNL group
glycemic control deteriorated from week 12 to week 24 in direct
proportion to decreased SMBG frequency. Lack of standardization of
meters used by CNL patients is also a possible limitation due to
differences in meter testing procedures and ease of use.
In conclusion, this is the ﬁrst study to explore the potential
impact of an integrated strip-free SMBG system on SMBG frequency
and glycemic control in a large, international patient population.
Results from the ExAct study demonstrated that the use of the Accu-
Chek Mobile System can lead to signiﬁcant increases in the fre-
quency of SMBG tests towards guideline-recommended values in
A. Maran et al. / Journal of Clinical & Translational Endocrinology 1 (2014) 161e166166previously non-adherent patients and to improvements in glycemic
control. Importantly, the SMBG and glycemic improvements seen
with the integrated strip-free technology were maintained
throughout the study period, suggesting that patients had better
awareness of their glucose levels and were able to make the neces-
sary adjustments to their medication and diet in a timely manner,
thus supporting adherence to their medication. Although additional
studies are needed to further stratify the changes in SMBG testing
frequency to type 1 or type 2 diabetes patients in order to determine
whether one type of patient is more responsive to the new tech-
nology than the other, our ﬁndings suggest that the beneﬁts of an
integrated strip-free SMBG system may be generalizable across a
large range of individuals with insulin-treated diabetes.Acknowledgments
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